Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook
BRISTOL MYERS SQUIBB CO (BMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress • Second quarter revenues increased 6% (+5% Ex-FX) to $13.0 billion ◦ Growth Portfolio r
How this was made
The 30-second read
Why it matters
The key tradable items are the Q2 financial prints (GAAP and non-GAAP EPS) and the raised 2026 revenue and non-GAAP EPS guidance ranges, plus product-level drivers (Growth Portfolio up 15% and Eliquis demand strength).
Market read
Guidance raise plus strong Growth Portfolio growth is likely to be the dominant driver for positioning, while product mix and legacy declines frame the risk.
What to watch
Non-GAAP includes acquired IPRD and licensing impacts; gross margin and R&D dynamics (priority review voucher, IPRD impairment charges) may affect sustainability of earnings quality.
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook
Total revenues increased 6% to $13.0 billion, Growth Portfolio revenues increased 15% to $7.6 billion, and the company raised its 2026 revenue and non-GAAP EPS outlook. Growth was tempered by a 4% decline in Legacy Portfolio revenues and a 120-basis-point decline in both GAAP and non-GAAP gross margin.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total Revenuesother | $12.97B | – | 6 % |
| Earnings/(Loss) Per ShareGAAP | $1.62 per share | – | 153 % |
| Earnings/(Loss) Per Sharenon-GAAP | $2.04 per share | – | 40 % |
| Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Shareother | $0.01 per share | – | N/A |
| Cost of products soldGAAP | $3.73B | – | 11% |
| Cost of products soldnon-GAAP | $3.71B | – | 11% |
| Gross marginGAAP | 71.3 % | – | (120) bps |
| Gross marginnon-GAAP | 71.4 % | – | (120) bps |
| Selling, general and administrativeGAAP | $1.83B | – | 7% |
| Selling, general and administrativenon-GAAP | $1.83B | – | 8% |
| Research and developmentGAAP | $2.96B | – | 15% |
| Research and developmentnon-GAAP | $2.32B | – | 2% |
| Acquired IPRDGAAP | — | – | (100)% |
| Acquired IPRDnon-GAAP | — | – | (100)% |
| Amortization of acquired intangible assetsGAAP | $437M | – | (47)% |
| Other (income)/expense, netGAAP | −$61M | – | NM |
| Other (income)/expense, netnon-GAAP | $126M | – | NM |
| Effective tax rateGAAP | 18.8 % | – | (710) bps |
| Effective tax ratenon-GAAP | 16.5 % | – | 40 bps |
| Net income attributable to Bristol Myers SquibbGAAP | $3.3B | – | – |
| Net income attributable to Bristol Myers Squibbnon-GAAP | $4.2B | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. revenuesReported U.S. revenues increased 6%. | $9B | – | 6% |
| International revenuesReported International revenues increased 6%, or 5% Ex-FX. | $4B | – | 6% |
| Total Growth PortfolioRevenue growth was primarily driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. | $7.56B | – | 15 % |
| OpdivoWorldwide product revenue reported. | $2.48B | – | (3) % |
| Opdivo QvantigWorldwide product revenue reported. | $261M | – | >200% |
| OrenciaWorldwide product revenue reported. | $1.03B | – | 7 % |
| YervoyWorldwide product revenue reported. | $769M | – | 6 % |
| ReblozylWorldwide product revenue reported. | $735M | – | 29 % |
| BreyanziWorldwide product revenue reported. | $484M | – | 41 % |
| OpdualagWorldwide product revenue reported. | $349M | – | 23 % |
| CamzyosWorldwide product revenue reported. | $416M | – | 60 % |
| ZeposiaWorldwide product revenue reported. | $169M | – | 12 % |
| SotyktuWorldwide product revenue reported. | $87M | – | 23 % |
| KrazatiWorldwide product revenue reported. | $55M | – | 14 % |
| CobenfyWorldwide product revenue reported. | $63M | – | 81 % |
| Other Growth ProductsIncludes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair. | $653M | – | 17 % |
| Total Legacy PortfolioDemand increased for Eliquis, which was more than offset by expected continued generic impacts across the remainder of the Legacy Portfolio. | $5.42B | – | (4) % |
| EliquisWorldwide product revenue reported. | $4.48B | – | 22 % |
| RevlimidWorldwide product revenue reported. | $425M | – | (49) % |
| Pomalyst/ImnovidWorldwide product revenue reported. | $204M | – | (71) % |
| SprycelWorldwide product revenue reported. | $88M | – | (27) % |
| AbraxaneWorldwide product revenue reported. | $55M | – | (47) % |
| Other Legacy ProductsIncludes other mature brands. | $170M | – | (24) % |
| Other RevenueIncludes revenue hedging activities in 2026. | −$9M | – | N/A |
2026 full-year outlook outlook
- Revenue~$49.0 billion to $50.0 billion
- NoteNon-GAAP EPS: $6.75 to $7.00
What drove it
- Growth Portfolio revenues increased 15%, or 14% Ex-FX, to $7.6 billion.
- Growth Portfolio revenue growth was primarily driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag.
- Eliquis worldwide revenue increased 22% to $4,481 million.
- Cobenfy worldwide revenue increased 81% to $63 million.
- The company raised 2026 revenue guidance to ~$49.0 billion to $50.0 billion and increased its non-GAAP EPS range to $6.75 to $7.00.
Concerns
- Legacy Portfolio revenues decreased 4%, or 5% Ex-FX, to $5.4 billion.
- Revlimid worldwide revenue declined 49% to $425 million and Pomalyst/Imnovid worldwide revenue declined 71% to $204 million.
- GAAP and non-GAAP gross margin each decreased 120 bps, primarily reflecting a change in product mix.
- GAAP research and development expenses increased 15%, primarily driven by the purchase of a priority review voucher and higher IPRD impairment charges in 2026.
- Other (income)/expense, net reflects the expiry of royalty income on diabetes products at the end of 2025.
What to watch
- FDA PDUFA date of March 11, 2027 for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions.
- FDA PDUFA date of May 13, 2027 for mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
- PDUFA date of August 17, 2026 for iberdomide for an RRMM indication.
- Commercial execution for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag and Cobenfy.
- Continued generic impacts across the Legacy Portfolio.
Analysis
Bristol Myers Squibb reported second-quarter total revenues of $12,973 million, up 6%, or 5% Ex-FX. The principal growth engine was the Growth Portfolio, where revenue increased 15% to $7,560 million. The release identifies Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag as the primary contributors. Eliquis also delivered 22% worldwide revenue growth to $4,481 million.
Growth Portfolio performance contrasted with the Legacy Portfolio, where revenue declined 4% to $5,422 million. The company said higher Eliquis demand was more than offset by expected continued generic impacts elsewhere in the portfolio. Revenue declines included Revlimid at 49%, Pomalyst/Imnovid at 71%, Sprycel at 27%, Abraxane at 47%, and Other Legacy Products at 24%.
Profitability improved substantially versus the prior-year period on reported earnings measures. GAAP net income attributable to Bristol Myers Squibb was $3.3 billion, or $1.62 per share, compared with $1.3 billion, or $0.64 per share. Non-GAAP net income was $4.2 billion, or $2.04 per share, compared with $3.0 billion, or $1.46 per share. At the same time, GAAP and non-GAAP gross margin each fell 120 bps, primarily due to product mix, while GAAP R&D expense rose 15% due to a priority review voucher purchase and higher IPRD impairment charges.
The company raised its 2026 outlook, guiding revenue to ~$49.0 billion to $50.0 billion and non-GAAP EPS to $6.75 to $7.00. Pipeline developments included FDA acceptance of applications for Reblozyl and mezigdomide, with PDUFA dates of March 11, 2027 and May 13, 2027, respectively. The reported period therefore combines continued Growth Portfolio momentum and an upgraded full-year outlook with ongoing Legacy Portfolio erosion and lower gross margins.
Management, verbatim
The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business.
Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb
We are building from a position of strength and progressing a differentiated pipeline designed to generate long-term value. As a result of our consistent execution and continued momentum, we are raising our 2026 full-year outlook.
Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb
Not in the filing
stated, not guessed- Prior-quarter comparisons for total revenue, products, expenses, margins, net income and EPS
- GAAP operating income
- Non-GAAP operating income
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Share count
- Full 2026 gross-margin guidance
- Full 2026 operating-expense guidance
- Full 2026 tax-rate guidance
- Prior-quarter outlook for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K with the company’s Q2 2026 results and accompanying press release (Exhibit 99.1).
Ticker impact
Bristol Myers Squibb reported Q2 2026 results and raised full-year revenue guidance to about $49.0B to $50.0B.
Likely positive bias for the stock on the guidance raise, with follow-through tied to whether Growth Portfolio momentum persists.
The filing includes specific Q2 revenue/EPS prints and a quantified full-year guidance increase, which are direct drivers of valuation and positioning.
Market effects
Signals continued strength in oncology and hematology franchises, potentially supporting sentiment for large-cap pharma with similar product-mix dynamics.
No explicit regional macro shock; both U.S. and international revenues grew 6% in Q2.
Guidance raise can influence broader expectations for pharma revenue growth and pipeline monetization.
Counterpoint
Legacy Portfolio declines (Eliquis demand offset by generic impacts) could reassert pressure if Growth Portfolio growth slows or if pipeline timelines slip.
Key entities
- issuerBristol Myers Squibb Company
Reported Q2 2026 results and raised full-year 2026 outlook in the 8-K press release.
- regulatorU.S. FDA
Accepted supplemental BLA for Reblozyl with a PDUFA date of March 11, 2027, and accepted an NDA for mezigdomide with a PDUFA date of May 13, 2027.
